Serum IL-10 as a marker of severe dengue infection

Malavige, Gathsaurie Neelika; Gomes, Laksiri; Alles, Lukmall; Chang, Thashi; Salimi, Maryam; Fernando, Sudheera R.; Nanayakkara, Kushan Dhanuja Liyanage; Jayaratne, S D; Ogg, Graham S.

doi:10.1186/1471-2334-13-341

Cited by 83 publications

(71 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten studies noted affirmatively that their first blood sampling was performed at the febrile phase, which we defined here as <5 days or <96 h from fever onset (Brasier et al, 2012;Butthep et al, 2012;Green et al, 1999a, b;De La Cruz Hern andez et al, 2014;Malavige et al, 2013a;P erez et al, 2004;Soundravally et al, 2014;Wang et al, 2007). The remaining studies had wider blood sampling windows, ranging from 1 to 10 days from symptom onset (Arias et al, 2014;Bozza et al, 2008;Chen et al, 2005;de-Oliveira-Pinto et al, 2012;Guerrero et al, 2013;Houghton-Triviño et al, 2010;Kurane et al, 1991Kurane et al, , 1993Laur et al, 1998;Levy et al, 2010;Del Moral-Hern andez et al, 2014;Nguyen et al, 2004;Suharti et al, 2003).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…A total of 19 out of 24 studies were case-control studies (Arias et al, 2014;Bozza et al, 2008;Brasier et al, 2012;Butthep et al, 2012;Chen et al, 2005;Furuta et al, 2012;Green et al, 1999a, b;Guerrero et al, 2013;Houghton-Triviño et al, 2010;De La Cruz Hern andez et al, 2014;Laur et al, 1998;Levy et al, 2010;Malavige et al, 2013a;Nguyen et al, 2004;Del Moral-Hern andez et al, 2014;P erez et al, 2004;Soundravally et al, 2014;Wang et al, 2007), and the remaining 5 studies were prospective cohort studies (de-Oliveira-Pinto et al, 2012;Kurane et al, 1991Kurane et al, , 1993Suharti et al, 2003). Comparison groups were healthy controls, patients with other febrile illness (OFI) or non-severe disease patients (DF or non-SD); however, comparisons made between SD and non-SD cases were considered most ideal for the purpose of this review.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Of the selected 24 studies, 4 studies (16.7 %) employed the WHO (2009) case definition (Arias et al, 2014;de-OliveiraPinto et al, 2012;Guerrero et al, 2013;Malavige et al, 2013a). Among them, one reported elevation in IL-10 (Malavige et al, 2013a), congruent with the seven WHO (1997) guideline-utilizing studies that reported elevations in IL-10 in DHF patients (Table 3), and one study reported elevated IL-10 levels in DwoWS, DwWS and SD patients compared to controls (Guerrero et al, 2013).…”

Section: Prognostication Marker Candidates: Who (2009) Sdmentioning

confidence: 99%

See 2 more Smart Citations

Markers of dengue severity: a systematic review of cytokines and chemokines

Lee

Leong

Wilder‐Smith

2016

Journal of General Virology

View full text Add to dashboard Cite

The prognosis of dengue remains a challenge in the early, objective triage of patients with dengue fever of differing severity. Circulating immuno-modulating proteins have brought new possibilities as prognostic markers of severe dengue (SD). This systematic review is devoted to understanding the potential utility of blood-based cytokines and chemokines as prognostication markers of SD based on the current literature. PubMed and Embase were searched. Of 794 candidate articles, 685 abstracts were screened against our exclusion/inclusion criteria and 25 (3.6 %) studies met the quality assessments. A total of 18 studies were retrospective observational and 2 were prospective cohort studies. Elevated IL-10, up to day 7 of fever onset, stood out as a candidate prognostic marker for SD using the 1997 and 2009 World Health Organization (WHO) case definitions. IFNg was another potential prognostic marker of SD (1997 WHO case definition), but its levels varied between studies. Significant heterogeneity in methodologies and patient cohorts prevent ready application of IL-10 and IFNg as prognostic markers to other dengue populations. Our results suggest that the current non-randomized studies are delivering inconsistent messages and higher-quality studies, with consistent methodologies and validation in independent patient cohorts, are needed to delineate confounding variables. Major gaps identified were full accounting and transparency of sampling days, dengue virus type, infection status and age group.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Prognostication Marker Candidates: Who (2009) Sdmentioning

confidence: 99%

See 1 more Smart Citation

Markers of dengue severity: a systematic review of cytokines and chemokines

Lee

Leong

Wilder‐Smith

2016

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…This model is a combination of the previous two models and is targeted at determining disease severity at an early stage. The combined interaction of inflammatory mediators together with immune parameters is of interest to study as, previous studies have shown that S1P levels are significantly correlated with platelet counts in DHF patients (Green, et al, 1999) and IL-10 levels are significantly and inversely correlated with lymphocyte counts (Malavige, et al, 2013). Furthermore, this model targets at reducing the number of parameters that are required for decision making.…”

Section: Introductionmentioning

confidence: 99%

Developing a Decision Support Testing Algorithm to Detect Severity Level of Dengue

Jayasundara

Perera

Rathnayaka

2017

ESJ

View full text Add to dashboard Cite

Dengue is a vector borne disease that has become a global threat. In order to reduce the mortality rate early detection of dengue severity level is crucial. This study is an extension of the decision models developed individually for inflammatory mediators and immune parameters. The objective of this study is to improve the individual models by considering their combined effect and to improve the decision making at 96 hours from onset of illness. In order to combine these, three approaches are attempted including, combining together the individual full models on inflammatory mediators and immune parameters, combining the immune parameters based model with decision tree informed cytokines and implementing a decision tree informed model with immune parameters and inflammatory mediators. The decision tree algorithm that is used in model development is Improved ID3 algorithm. The decision tree based model is a two-step decision system with the initial decision being made using the parameters TNF-α, IL-10, dengue NS1 antigen and dengue IgG antibody and, the operator values above 0.4413, are then subjected to the second test including platelet and Platelet Activating Factor. The decision tree based model performed well with an accuracy of 76.19% and 82.3% of DHF patients were correctly classified. Sensitivity analysis indicated the model to be robust.

show abstract

“…3 Previously identified markers of dengue severity include cytokines (i.e., tumor necrosis factor alpha [TNFα] and Interleukin 6 [IL-6]), vascular permeability proteins, clotting cascade regulators, and gene expression profiles. [4][5][6][7][8][9][10][11][12][13][14][15][16][17] These severity markers are not, however, currently being used to guide patient management. 18,19 It is unclear why these severity markers are not being used, possibly because detection methods are expensive, slow, or require sophisticated equipment.…”

Section: Introductionmentioning

confidence: 99%

Discovery and Characterization of Potential Prognostic Biomarkers for Dengue Hemorrhagic Fever

Poole-Smith

Gilbert

Gonzalez

et al. 2014

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Half a million patients are hospitalized with severe dengue every year, many of whom would die without timely, appropriate clinical intervention. The majority of dengue cases are uncomplicated; however, 2-5% progress to severe dengue. Severe dengue cases have been reported with increasing frequency over the last 30 years. To discover biomarkers for severe dengue, we used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to analyze dengue virus positive serum samples from the acute phase of infection. Using this method, 16 proteins were identified as candidate biomarkers for severe dengue. From these 16 biomarkers, three candidates were selected for confirmation by enzyme-linked immunosorbent assay and Western blot: vitronectin (Vtn, 55.1 kDa), hemopexin (Hx, 52.4 kDa), and serotransferrin (Tf, 79.2 kDa). Vitronectin, Hx, and Tf best differentiated between dengue and severe dengue.

show abstract

Serum IL-10 as a marker of severe dengue infection

Cited by 83 publications

References 16 publications

Markers of dengue severity: a systematic review of cytokines and chemokines

Markers of dengue severity: a systematic review of cytokines and chemokines

Developing a Decision Support Testing Algorithm to Detect Severity Level of Dengue

Discovery and Characterization of Potential Prognostic Biomarkers for Dengue Hemorrhagic Fever

Contact Info

Product

Resources

About